Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Cash from Investing Activities: 2009-2025

Historic Cash from Investing Activities for Aytu Biopharma (AYTU) over the last 11 years, with Jun 2025 value amounting to -$3.0 million.

  • Aytu Biopharma's Cash from Investing Activities fell 8773.53% to -$3.0 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$2.6 million, marking a year-over-year decrease of 678.12%. This contributed to the annual value of -$2.6 million for FY2025, which is 678.12% down from last year.
  • According to the latest figures from Q2 2025, Aytu Biopharma's Cash from Investing Activities is -$3.0 million, which was down 4,272.46% from -$69,000 recorded in Q1 2025.
  • In the past 5 years, Aytu Biopharma's Cash from Investing Activities ranged from a high of $381,000 in Q3 2024 and a low of -$3.1 million during Q4 2021.
  • In the last 3 years, Aytu Biopharma's Cash from Investing Activities had a median value of -$57,000 in 2024 and averaged -$304,300.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first plummeted by 10,070.00% in 2021, then spiked by 601.32% in 2024.
  • Quarterly analysis of 5 years shows Aytu Biopharma's Cash from Investing Activities stood at -$3.1 million in 2021, then spiked by 99.84% to -$5,000 in 2022, then plummeted by 3,380.00% to -$174,000 in 2023, then spiked by 183.33% to $145,000 in 2024, then crashed by 8,773.53% to -$3.0 million in 2025.
  • Its last three reported values are -$3.0 million in Q2 2025, -$69,000 for Q1 2025, and $145,000 during Q4 2024.